Merit Medical Systems ( (MMSI) ) has issued an update.
Merit Medical Systems reported a revenue of $355.4 million for the first quarter of 2025, marking a 9.8% increase from the previous year. The company also updated its full-year guidance, reflecting confidence in strong execution and stable growth, despite the potential impacts of recent trade policies.
Spark’s Take on MMSI Stock
According to Spark, TipRanks’ AI Analyst, MMSI is a Neutral.
Merit Medical Systems exhibits strong financial health with growing revenues and strategic advancements, such as FDA approval for new devices. However, the lack of net income for 2024 and poor technical indicators suggest caution. Valuation concerns also weigh on the stock, as it appears overvalued with no dividend yield. Despite these challenges, the positive earnings call and recent corporate achievements provide a balanced outlook.
To see Spark’s full report on MMSI stock, click here.
More about Merit Medical Systems
Merit Medical Systems, Inc. is a leading global manufacturer and marketer of healthcare technology, focusing on cardiovascular and endoscopy devices.
YTD Price Performance: -2.40%
Average Trading Volume: 696,381
Technical Sentiment Signal: Sell
Current Market Cap: $5.4B
Find detailed analytics on MMSI stock on TipRanks’ Stock Analysis page.